Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
encorafenib + cetuximab + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of encorafenib, cetuximab, and FOLFIRI is an investigational regimen for the treatment of metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Encorafenib is a small molecule inhibitor targeting the BRAF V600E mutant kinase, while cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR). FOLFIRI is a chemotherapy regimen consisting of fluorouracil (a pyrimidine analog antimetabolite), leucovorin (folinic acid, which enhances fluorouracil activity), and irinotecan (a topoisomerase I inhibitor). This combination has shown promising antitumor activity and tolerability in patients with previously treated or untreated BRAF V600E-mutant mCRC in clinical trials[1][2][5]. The mechanism involves dual blockade of oncogenic signaling pathways along with cytotoxic chemotherapy to maximize tumor control.
- Other names
- fluorouracil + leucovorin + irinotecan (for FOLFIRI)
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TOP1 (DNA Topoisomerase I)BRAF V600ETS (Thymidylate synthase)
Beyond the preview
Go deeper on encorafenib + cetuximab + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on encorafenib + cetuximab + FOLFIRI.